Skip to main content

Advertisement

Table 1 The overall distribution of the patients in different stages in our stratification groups of Fig. 5(d)

From: Integration of molecular features with clinical information for predicting outcomes for neuroblastoma patients

  Stage 1 (n = 10) Stage 2 (n = 21) Stage 3 (n = 33) Stage 4 s (n = 16) Stage 4 (n = 159)
Group 1 0% 0% 0% 37.5% 47%
Group 2 60% 52% 100% 6% 0%
Group 3 30% 0% 0% 6% 37%
Group 4 0% 48% 0% 37.5% 0%
Group 5 10% 0% 0% 13% 16%